Stokes Family Office LLC Increases Stock Position in Novo Nordisk A/S $NVO

Stokes Family Office LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 352.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,221 shares of the company’s stock after acquiring an additional 29,782 shares during the quarter. Stokes Family Office LLC’s holdings in Novo Nordisk A/S were worth $2,638,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Revolve Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares during the period. Bank of New York Mellon Corp increased its position in Novo Nordisk A/S by 6.0% during the 1st quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company’s stock valued at $58,316,000 after purchasing an additional 47,804 shares during the period. Penserra Capital Management LLC raised its holdings in Novo Nordisk A/S by 29.7% in the 1st quarter. Penserra Capital Management LLC now owns 7,831 shares of the company’s stock worth $543,000 after purchasing an additional 1,794 shares in the last quarter. U.S. Capital Wealth Advisors LLC lifted its position in shares of Novo Nordisk A/S by 26.6% in the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 8,773 shares of the company’s stock worth $609,000 after purchasing an additional 1,843 shares during the period. Finally, Linden Thomas Advisory Services LLC boosted its stake in shares of Novo Nordisk A/S by 12.8% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 4,011 shares of the company’s stock valued at $279,000 after purchasing an additional 456 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on NVO shares. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. HSBC set a $70.00 target price on Novo Nordisk A/S in a report on Wednesday, October 1st. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Finally, UBS Group downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $45.62 on Friday. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $112.52. The stock has a 50-day moving average of $55.32 and a 200 day moving average of $61.49. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The company has a market capitalization of $203.69 billion, a price-to-earnings ratio of 12.53, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.74 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.